Travere Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Travere Therapeutics es Eric Dube , nombrado en Jan 2019, tiene una permanencia de 5.83 años. compensación anual total es $7.57M, compuesta por 10.5% salario y 89.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.14% de las acciones de la empresa, por valor de $2.10M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 7.6 años, respectivamente.
Información clave
Eric Dube
Chief Executive Officer (CEO)
US$7.6m
Compensación total
| Porcentaje del salario del CEO | 10.5% |
| Permanencia del CEO | 5.8yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 4.1yrs |
| Promedio de permanencia en la Junta Directiva | 7.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry
Oct 31
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Oct 07Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Sep 30Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sep 10Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Aug 30Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now
May 02Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$349m |
| Jun 30 2024 | n/a | n/a | -US$383m |
| Mar 31 2024 | n/a | n/a | -US$416m |
| Dec 31 2023 | US$8m | US$796k | -US$376m |
| Sep 30 2023 | n/a | n/a | -US$373m |
| Jun 30 2023 | n/a | n/a | -US$368m |
| Mar 31 2023 | n/a | n/a | -US$352m |
| Dec 31 2022 | US$6m | US$747k | -US$331m |
| Sep 30 2022 | n/a | n/a | -US$297m |
| Jun 30 2022 | n/a | n/a | -US$249m |
| Mar 31 2022 | n/a | n/a | -US$202m |
| Dec 31 2021 | US$6m | US$708k | -US$217m |
| Sep 30 2021 | n/a | n/a | -US$250m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$224m |
| Dec 31 2020 | US$5m | US$661k | -US$169m |
| Sep 30 2020 | n/a | n/a | -US$78m |
| Jun 30 2020 | n/a | n/a | -US$92m |
| Mar 31 2020 | n/a | n/a | -US$105m |
| Dec 31 2019 | US$10m | US$618k | -US$146m |
Compensación vs. Mercado: La compensación total de Eric($USD7.57M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.38M).
Compensación vs. Ingresos: La compensación de Eric ha aumentado mientras la empresa no es rentable.
CEO
Eric Dube (51 yo)
5.8yrs
Permanencia
US$7,574,959
Compensación
Dr. Eric M. Dube, Ph D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.8yrs | US$7.57m | 0.14% $ 2.1m | |
| Chief Financial Officer | 2.3yrs | US$1.97m | 0.086% $ 1.3m | |
| Senior VP | 7.8yrs | US$2.02m | 0.090% $ 1.4m | |
| Senior VP and Head of Research & Development | 7.8yrs | US$2.05m | 0.041% $ 619.0k | |
| Chief Commercial Officer | 5.1yrs | US$2.00m | 0.068% $ 1.0m | |
| SVP, Corporate Controller & Chief Accounting Officer | 3.2yrs | sin datos | 0.060% $ 904.6k | |
| Vice President of Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Senior Vice President of Human Resources | no data | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos | |
| Chief Medical Officer | 2.8yrs | US$2.87m | 0.071% $ 1.1m | |
| Senior Vice President of Public Affairs | no data | sin datos | sin datos |
4.1yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TVTX se considera experimentado (4.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.8yrs | US$7.57m | 0.14% $ 2.1m | |
| Independent Director | 7.7yrs | US$372.98k | 0.033% $ 502.2k | |
| Independent Chairman of the Board | 10.1yrs | US$392.98k | 0.059% $ 886.9k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.6yrs | US$372.36k | 0.026% $ 386.9k | |
| Independent Director | 8.4yrs | US$376.73k | 0.036% $ 539.1k | |
| Independent Director | 3.2yrs | US$365.48k | 0.022% $ 334.8k | |
| Independent Director | 9.7yrs | US$385.48k | 0.056% $ 852.1k | |
| Independent Director | 7.6yrs | US$367.98k | 0.033% $ 502.2k | |
| Independent Director | 10.1yrs | US$379.98k | 0.093% $ 1.4m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.5yrs | US$369.86k | 0.027% $ 408.7k |
7.6yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de TVTX se considera experimentada (7.6 años de antigüedad promedio).